Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02429570 : Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary
PhaseN/A
AgesMin: 18 Years Max: 80 Years
Eligibility
Inclusion Criteria:

- Age 18-80

- KPS ? 60

- At least one recurrent or progressive brain metastasis (es) from any solid primary
tumor that is visible on MRI as assessed by the patient's treating physician.

- Recurrence may occur after any treatment: recurrence after whole-brain radiation,
stereotactic radiosurgery, surgical resection, systemic chemotherapy are all
acceptable.

- There is no limit on the number of brain metastases.

- Surgical resection or SRS to other recurrent lesions in the same patient are
acceptable, provided one recurrent lesion remains untreated.

- Systemic disease must be well-controlled or NED in the opinion of the patient's
primary oncologist.

Exclusion Criteria:

- Inability to get brain MRI +/- contrast

- Progressive systemic disease

- Known leptomeningeal metastases

- Primary Brain tumor

- Active Intracranial Hemorrhage

- Surgery less than two weeks before enrollment

- GI hemorrhage (active or in recent 6 months)

- Concurrent anti-platelet therapy

- Concurrent anti-coagulation therapy

- Active bleeding diathesis

- Platelet count ? 70,000/mm3

- International normalized ratio (INR) > 1.6 and a Partial Thromboplastin Time (PTT) >
40 seconds

- Serum Creatinine >2 mg/dL OR CrCL <30ml/min

- AST or ALT > 200 U/L

- Hemoglobin <8 g/dL

- Allergy to meclofenamate or other NSAID

- Inability to tolerate PO dosing

- Steroid dose increased in the most recent two weeks.

- Pregnancy

- Cardiac Arrhythmia requiring medical management and/or pacemaker.

- Known congestive heart failure requiring medical management
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02429570      |      Link to official Clinicaltrials.gov listing
Locations
Miami, Florida
Facility: Baptist Health South Florida
Investigator:
Contact: Yazmin Odia, MD Phone: 786-596-2000
Email not avaialable

Basking Ridge, New Jersey
Facility: Memoral Sloan Kettering Cancer Center
Investigator:
Contact: Adrienne Borie, MD, PhD Phone: 212-639-5371
Email not avaialable

Middletown, New Jersey
Facility: Memorial Sloan Kettering Monmouth
Investigator:
Contact: Adrienne Boire, MD Phone: 212-639-5371
Email not avaialable

Commack, New York
Facility: Memorial Sloan Kettering Cancer Center at Commack
Investigator:
Contact: Adrienne Boire, MD, PhD Phone: 212-639-5371
Email not avaialable

Harrison, New York
Facility: Memorial Sloan Kettering Westchester
Investigator:
Contact: Adrienne Boire, MD, PhD Phone: 212-639-5371
Email not avaialable

New York, New York
Facility: Memorial Sloan Kettering Cancer Center
Investigator: Adrienne Boire, MD, PhD
Contact: Adrienne Boire, MD, PhD Phone: 212-639-5371
Email not avaialable

Allentown, Pennsylvania
Facility: Lehigh Valley Health Network
Investigator:
Contact: Suresh Nair, MD Phone: 610-402-7880
Email not avaialable




Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740